CD20 Antibody (CL10613) - Azide and BSA Free

Novus Biologicals | Catalog # NBP3-43919

Novus Biologicals

Key Product Details

Validated by

Orthogonal Validation

Species Reactivity

Human

Applications

Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # CL10613

Format

Azide and BSA Free
View all CD20 Primary Antibodies »

Product Specifications

Immunogen

This antibody was generated using a recombinant protein sequence of P11836, with the exact immunogen sequence remaining proprietary.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Description

Novus Biologicals Mouse CD20 Antibody (CL10613) - Azide and BSA Free (NBP3-07979) is a monoclonal antibody validated for use in IHC and WB. All Novus Biologicals antibodies are covered by our 100% guarantee.

Scientific Data Images for CD20 Antibody (CL10613) - Azide and BSA Free

CD20 Antibody (CL10613) - Azide and BSA Free Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Analysis in human lymph node and cerebral cortex tissues using NBP3-43919 antibody. Corresponding CD20 RNA-seq data are presented for the same tissues.
CD20 Antibody (CL10613) - Azide and BSA Free Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Staining of human cerebral cortex shows no positivity in neurons as expected.
CD20 Antibody (CL10613) - Azide and BSA Free Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Staining of human colon shows strong membranous positivity in a small subset of lymphoid cells.
CD20 Antibody (CL10613) - Azide and BSA Free Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Staining of human liver shows no positivity in hepatocytes as expected.
CD20 Antibody (CL10613) - Azide and BSA Free Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Immunohistochemistry-Paraffin: CD20 Antibody [NBP3-43919]

Staining of human lymph node shows strong membranous positivity in germinal center cells.
CD20 Antibody (CL10613) - Azide and BSA Free Western Blot: CD20 Antibody [NBP3-43919]

Western Blot: CD20 Antibody [NBP3-43919]

Analysis in human cell line Daudi.

Applications for CD20 Antibody (CL10613) - Azide and BSA Free

Application
Recommended Usage

Immunohistochemistry-Paraffin

1:500 - 1:1000

Western Blot

1 ug/ml
Application Notes
For IHC-Paraffin, HIER pH 6 retrieval is recommended.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Centrifuge the vial of lyophilized antibody at 12,000 x g for 20 seconds. Reconstitute by adding sterile, distilled water to achieve a final antibody concentration of 1mg/ml.

Formulation

Lyophilized from a 0.2 um filtered solution in PBS with Trehalose

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CD20

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Long Name

Cluster of Differentiation 20

Alternate Names

B1, Bp35, CD20, LEU-16, Ly-44, MS4A1, S7

Gene Symbol

MS4A1

Additional CD20 Products

Product Documents for CD20 Antibody (CL10613) - Azide and BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for CD20 Antibody (CL10613) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customer Reviews for CD20 Antibody (CL10613) - Azide and BSA Free

There are currently no reviews for this product. Be the first to review CD20 Antibody (CL10613) - Azide and BSA Free and earn rewards!

Have you used CD20 Antibody (CL10613) - Azide and BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies